and increased portal pressure has been found, even in the absence of portal vein thrombosis. Datta et al. (1975) (Fusco and Rosen, 1966; Cottrell et al., 1969) . The histology of these tumours is usually anaplastic large cell carcinoma but Cottrell et al. (1969) reported cases of squamous cell, adenocarcinoma and oat cell carcinoma. The origin of the gonadotrophins has been ascribed to tumour cells. Assay of tumour tissue (Dailey and Marcuse, 1969) hormone location by immunofluorescence (Becker et al., 1968) and arteriovenous difference of hormone levels across the tumour bed (Faiman et al., 1967) seem to support this. The origin of the raised serum oestrogen is less clear. It has been suggested that testicular and adrenal stimulation by the circulatory gonadotrophins is responsible (Fusco and Rosen, 1966; Cottrell et al., 1969) , but Kirschner, Cohen and Jespersen (1974) raised the possibility that the tumour itself released oestrogens. Whether gynaecomastia develops directly as a result of the tumour secreting oestrogens, gonadotrophins, androgens or thyroid hormones or through hormones elaborated by secondary stimulation of end organs is speculative (Bannayan and Hajdu, 1972; Treves, 1958) . This patient had no clinical evidence to suggest elaboration of other hormones.
In a series of patients with bronchogenic carcinoma, half of whom had gynaecomastia, there was no difference in oestrogen secretion between the two groups (Ginsburg, 1969) . One might expect gynaecomastia to be bilateral but Hamer (1975) reports that in over 75% of cases the condition is unilateral; the left breast being affected more often than the right; this is reported elsewhere (Bannayan and Hajdu, 1972) .
Gynaecomastia is known to be associated with drugs (Meyler and Herxheimer, 1972) . The only such drug taken by the patient was vincristine (Smith and Barrett, 1967) . The association with this drug has only been reported once and is unconfirmed. In the present patient the vincristine was discontinued 15 weeks before his gynaecomastia developed.
Tamoxifen is an anti-oestrogen. This agent has been shown in rats to oppose the effects of exogenously administered oestrogen (Prasad and Sarkaran, 1972; Cole, Jones and Todd, 1971) . This is thought to be due to competition for oestrogenbinding sites in end organs. Gonadotrophin levels are unaffected. In man, anti-oestrogens have been used to interrupt the pituitary-ovarian axis and to produce regression in advanced breast cancer (Cole et al., 1971; Ward, 1973; Bloom and Boesen, 1974) . The association of dermatomyositis with malignancy is well known (Grace and Dao, 1959; Brunner and Lobraico, 1951) and has been reviewed by Williams (1959) and Arundell, Wilkinson and Haserick (1960 
